KHKeishi Higashi

Keishi Higashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Keishi Higashi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice

    by Keishi Higashi, Takashi Oda, Taketoshi Kushiyama, Toshitake Hyodo, Muneharu Yamada, Shigenobu Suzuki, Yutaka Sakurai, Soichiro Miura, Hiroo Kumagai

    To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO). Mice were randomly assigned into four groups that after UUO received i.p. injections of either Pio (10 mg/kg/day), Cand (1 mg/kg/day), Cand + Pio or vehicle for 10 days. Physiological parameters, the degree of renal fibrosis and molecules related to renal fibrosis were analysed, and sham-operated mice were used as controls. Total collagen assay showed prominent renal fibrosis in the vehicle-treated mice, significantly attenuated renal fibrosis in the Cand-treated and the Pio-treated mice, and further attenuated renal fibrosis in the (Cand + Pio)-treated mice. Real-time reverse transcription polymerase chain reaction revealed that this attenuation pattern was also evident in the expression of the mRNA for transforming growth factor-beta, collagens I and III, and plasminogen activator inhibitor-1. Pioglitazone and candesartan have additive protective effects on renal fibrosis due to UUO in mice, suggesting that their use in combination would be an effective treatment for chronic kidney disease.